Stock analysis, AI verdict, fundamentals & technical signals
Rating: BUY
Price: $5.84 Analyst target: $11.33 Upside: 94.01%
LENSAR, Inc., a commercial stage medical device company, is focused on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company is headquartered in Orlando, Florida.
See the full interactive analysis & chart →Informational only — not investment advice.